These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas. Kim HS; Kwon MJ; Song JH; Kim ES; Kim HY; Min KW Pathol Res Pract; 2018 Jun; 214(6):881-888. PubMed ID: 29650441 [TBL] [Abstract][Full Text] [Related]
5. Molecular prognostic factors of anaplastic oligodendroglial tumors and its relationship: a single institutional review of 77 patients from China. Li S; Yan C; Huang L; Qiu X; Wang Z; Jiang T Neuro Oncol; 2012 Jan; 14(1):109-16. PubMed ID: 22039037 [TBL] [Abstract][Full Text] [Related]
6. Prognostic value of MGMT promoter methylation and TP53 mutation in glioblastomas depends on IDH1 mutation. Wang K; Wang YY; Ma J; Wang JF; Li SW; Jiang T; Dai JP Asian Pac J Cancer Prev; 2014; 15(24):10893-8. PubMed ID: 25605197 [TBL] [Abstract][Full Text] [Related]
7. Molecular Characteristics of Thalamic Gliomas in Adults. Wang T; Niu X; Gao T; Zheng L; Qiu Y; Mao Q J Mol Neurosci; 2021 Aug; 71(8):1598-1604. PubMed ID: 33523385 [TBL] [Abstract][Full Text] [Related]
8. Prognostic and predictive value of p53 in low MGMT expressing glioblastoma treated with surgery, radiation and adjuvant temozolomide chemotherapy. Li S; Zhang W; Chen B; Jiang T; Wang Z Neurol Res; 2010 Sep; 32(7):690-4. PubMed ID: 19703338 [TBL] [Abstract][Full Text] [Related]
9. The expression of p53, mgmt and egfr in brain glioma and clinical significance. Lin T; Wang M; Liang HS; Liu EZ J Biol Regul Homeost Agents; 2015; 29(1):143-9. PubMed ID: 25864751 [TBL] [Abstract][Full Text] [Related]
10. Potential Role of Methylation Marker in Glioma Supporting Clinical Decisions. Roszkowski K; Furtak J; Zurawski B; Szylberg T; Lewandowska MA Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27834917 [TBL] [Abstract][Full Text] [Related]
11. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation. Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593 [TBL] [Abstract][Full Text] [Related]
12. Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation. Wick W; Meisner C; Hentschel B; Platten M; Schilling A; Wiestler B; Sabel MC; Koeppen S; Ketter R; Weiler M; Tabatabai G; von Deimling A; Gramatzki D; Westphal M; Schackert G; Loeffler M; Simon M; Reifenberger G; Weller M Neurology; 2013 Oct; 81(17):1515-22. PubMed ID: 24068788 [TBL] [Abstract][Full Text] [Related]
13. Combined IDH1 mutation and MGMT methylation status on long-term survival of patients with cerebral low-grade glioma. Tanaka K; Sasayama T; Mizukawa K; Takata K; Sulaiman NS; Nishihara M; Kohta M; Sasaki R; Hirose T; Itoh T; Kohmura E Clin Neurol Neurosurg; 2015 Nov; 138():37-44. PubMed ID: 26276726 [TBL] [Abstract][Full Text] [Related]
14. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. Weller M; Felsberg J; Hartmann C; Berger H; Steinbach JP; Schramm J; Westphal M; Schackert G; Simon M; Tonn JC; Heese O; Krex D; Nikkhah G; Pietsch T; Wiestler O; Reifenberger G; von Deimling A; Loeffler M J Clin Oncol; 2009 Dec; 27(34):5743-50. PubMed ID: 19805672 [TBL] [Abstract][Full Text] [Related]
15. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas. Houdova Megova M; Drábek J; Dwight Z; Trojanec R; Koudeláková V; Vrbková J; Kalita O; Mlcochova S; Rabcanova M; Hajdúch M Klin Onkol; 2017; 30(5):361-371. PubMed ID: 29031038 [TBL] [Abstract][Full Text] [Related]
16. Association between small heat shock protein B11 and the prognostic value of MGMT promoter methylation in patients with high-grade glioma. Cheng W; Li M; Jiang Y; Zhang C; Cai J; Wang K; Wu A J Neurosurg; 2016 Jul; 125(1):7-16. PubMed ID: 26544773 [TBL] [Abstract][Full Text] [Related]
17. Low MGMT digital expression is associated with a better outcome of IDH1 wildtype glioblastomas treated with temozolomide. Gomes I; Moreno DA; Dos Reis MB; da Silva LS; Leal LF; Gonçalves GM; Pereira CA; Oliveira MA; de Medeiros Matsushita M; Reis RM J Neurooncol; 2021 Jan; 151(2):135-144. PubMed ID: 33400009 [TBL] [Abstract][Full Text] [Related]
18. [IDH1 mutation and MGMT expression in astrocytoma and the relationship with prognosis after radiotherapy]. Jiang M; Dong X; Li J; Li J; Qi J Zhonghua Bing Li Xue Za Zhi; 2014 Oct; 43(10):668-72. PubMed ID: 25567592 [TBL] [Abstract][Full Text] [Related]
19. Gliomatosis cerebri: no evidence for a separate brain tumor entity. Herrlinger U; Jones DTW; Glas M; Hattingen E; Gramatzki D; Stuplich M; Felsberg J; Bähr O; Gielen GH; Simon M; Wiewrodt D; Schabet M; Hovestadt V; Capper D; Steinbach JP; von Deimling A; Lichter P; Pfister SM; Weller M; Reifenberger G Acta Neuropathol; 2016 Feb; 131(2):309-319. PubMed ID: 26493382 [TBL] [Abstract][Full Text] [Related]
20. IDH1 mutations is prognostic marker for primary glioblastoma multiforme but MGMT hypermethylation is not prognostic for primary glioblastoma multiforme. Kalkan R; Atli Eİ; Özdemir M; Çiftçi E; Aydin HE; Artan S; Arslantaş A Gene; 2015 Jan; 554(1):81-6. PubMed ID: 25455102 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]